Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C
ProcedureInitiated Standard DAA treatment among HCV RNA positive patients.
NCT Number: NCT06952036
The objectives of this study are to improve HCV linkage-to-care in Chinese women and provide theoretical basis for the scientific formulation of HCV prevention and control strategies for pregnant women.
To understand the epidemiological changes and status of hepatitis C virus (HCV) infection in pregnant women in Shaanxi province in recent 10 years, and to analyze the main influencing factors of hepatitis C infection in pregnant women.
Trial opening soon.
Get Notified18 year and older
Female
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Initiated Standard DAA treatment among HCV RNA positive patients.
Time frame: From enrollment to the end of treatment at 12 weeks
The percentage of patients receiving DAA treatment among the diagnosed but untreated patients.
Contact information is provided by the study sponsor or research team.
First Affiliated Hospital Xi'an Jiaotong University
Other
The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an: A 10-Year Retrospective Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07412977
Arbovirus Infections, Blood-Borne Infections
Paris, France
View Trial DetailsNCT07241962
Blood-Borne Infections, Communicable Diseases
View Trial DetailsNCT01463956
Blood-Borne Infections, Communicable Diseases
Bordeaux, France
View Trial DetailsNCT05992077
Blood-Borne Infections, Communicable Diseases
Battambang, Cambodia
View Trial Details